My thesis argues that Sanofi is a buy today. I think the driving factor of this thesis with the greatest weight to my buy ...

with an initial rollout expected for phase 3 tests of Sanofi’s multiple sclerosis meds. Here’s how the tool is designed: ...

Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for clinical ...

Backed by a $1 million grant, researchers at Case Western Reserve University in Ohio will explore ways to keep astrocytes in ...

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The quest to understand and slow disease ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Global Central Nervous System Therapeutics Market is valued at approximately USD 143.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period ...

Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader ... The study was supported by Sanofi.

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...